Results 141 to 150 of about 83,454 (234)

Weaknesses out of strength: PNA against the penicillin-binding proteins. [PDF]

Mol Ther Nucleic Acids
Wdowiak M.
europepmc   +1 more source

Enhanced liver-targeted delivery with ribofuranose-based GalNAc conjugates. [PDF]

Mol Ther Nucleic Acids
Pradeep SP, Ruchi R, Bahal R.
europepmc   +1 more source

Systemic distribution of tricyclo-DNA antisense oligonucleotide following intratracheal instillation in the mouse. [PDF]

NAR Mol Med
Laurent J, Deramaudt TB, Cloix R, Robin V, Beley C, Garcia L, Bonay M.   +6 more
europepmc   +1 more source

Synthesis of siRNAs containing carbocyclic nucleotides and the role of cyclopentane conformation in RNAi activity. [PDF]

RSC Chem Biol
Kundu J, Datta D, Akabane-Nakata M, Mandal S, Krampert M, Egli M, Manoharan M.   +6 more
europepmc   +1 more source

Cortisol response to corticotropin and survival in septic shock [PDF]

, 1991
Angeles Marcos, Breder, Bruno Allolio, Esteban Martínez, GilbertR Park, Gleadle, Martin Reincke, Michie, Niraj Varma, Park, Peter Vadas, Schein, Sibbald, Vadas, Vadas, Varma, Voerman, Waldemar Pruzanski, Werner Winkelmann   +18 more
core   +1 more source

RNA-Based Therapies for Inherited Metabolic Disorders. [PDF]

J Inherit Metab Dis
Vootukuri RS, Gurung S, Ghosh R, Mills PB, Baruteau J, Zhou H.   +5 more
europepmc   +1 more source

Rescue of mitochondrial power outages with γPNA-based miR-122 inhibitor. [PDF]

Mol Ther Nucleic Acids
Mukherjee K, Bhattacharyya SN.
europepmc   +1 more source

Application of Antisense Oligonucleotides as an Alternative Approach for Gene Expression Control and Functional Studies. [PDF]

Int J Mol Sci
Szukowska A, Żuk M, Sztompke J, Bednarz B, Kaźmierczak U.   +4 more
europepmc   +1 more source

Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia. [PDF]

Front Oncol
Lin HY, Khou S, Lind E, de Oliveira Rebola KG, Dean A, Zhang H, Tolentino A, Maazi H, Revenko A, Agarwal A.   +9 more
europepmc   +1 more source

Selective silencing of expanded CAG repeats: Chemically modified siRNA advances RNA-based therapies for polyglutamine diseases. [PDF]

Mol Ther Nucleic Acids
Scholten GJ, Hyde JT, Buijsen RAM.
europepmc   +1 more source